Whither Recombinant Human Growth Hormone?
Authors: Christos S. Mantzoros
Journal: Annals of Internal Medicine (1996)

Editorials1 December 1996Whither Recombinant Human Growth Hormone?Christos S. Mantzoros, MD, DSc and Alan C. Moses, MDChristos S. Mantzoros, MD, DScBeth Israel Deaconess Medical Center, Boston, MA 02215.Search for more papers by this author and Alan C. Moses, MDBeth Israel Deaconess Medical Center, Boston, MA 02215.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-125-11-199612010-00010 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Growth hormone and insulin-like growth factor 1 (IGF-1) are important anabolic hormones. They enhance intestinal absorption of calcium and phosphate and may play a direct role in DNA synthesis in bone, proliferation of osteoblasts, and accumulation of procollagen messenger RNA [1, 2]. Although the actions of growth hormone were thought to be caused by circulating IGF-1 alone, recent evidence [1, 2] suggests that growth hormone and other hormones stimulate local production of IGF-1, which acts in a paracrine-autocrine fashion in some tissues.Starvation and cachexia (including that seen in patients with wasting associated with the acquired immunodeficiency syndrome [AIDS]) are ...References1. Copras E, Harman M, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993; 14:20-39. Google Scholar2. Bondy CA, Underwood LE, Clemmons DR, Guler HP, Bach MA, Skarulis M. Clinical uses of insulin-like growth factor 1. Ann Intern Med. 1994; 120:593-601. Google Scholar3. Papadakis MA, Grady D, Black D, Tierney MJ, Gooding GA, Schambelan M, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med. 1996; 124:708-16. Google Scholar4. Mantzoros CS, Flier JS. Insulin resistance: the clinical spectrum. Adv Endocrinol Metab. 1995; 6:193-232. Google Scholar5. Underwood LE. Growth hormone therapy for short stature: yes or no? Hosp Pract (Off Ed). 1992; 27:192-6, 198. Google Scholar6. Drug abuse in athletes. Anabolic steroids and human growth hormone. Council on Scientific Affairs. JAMA. 1988; 259:1703-5. Google Scholar7. Jorgensen JO, Pedersen SA, Thuesen L, Jorgensen J, Ingemenn-Hansen T, Skakkebaek NE, et al. Beneficial effects of growth hormone treatment in GH-deficlent adults. Lancet. 1989; 1:1221-5. Google Scholar8. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990; 323:1-6. Google Scholar9. Waters D, Danska J, Hardy K, Koster F, Qualls C, Nickell D, et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996; 125:865-72. Google Scholar10. Ponting GA, Halliday D, Teale JD, Sim AJ. Postoperative positive nitrogen balance with intravenous hyponutrition and growth hormone. Lancet. 1988; 1:438-40. Google Scholar11. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab. 1993; 77:956-62. Google Scholar12. Lieberman SA, Butterfield GE, Harrison D, Hoffman AR. Anabolic effects of recombinant insulin-like growth factor-1 in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1994; 78:404-10. Google Scholar13. Ellis KJ, Lee PD, Pivarnik JM, Bukar JG, Gesundheit N. Changes in body composition of human immunodeficiency virus-infected males receiving insulin-like growth factor 1 and growth hormone. J Clin Endocrinol Metab. 1996; 81:3033-8. Google Scholar14. Lee PD, Pivarnik JM, Bukar JG, Muurahainen N, Berry PS, Skolnik PR, et al. A randomized, placebo-controlled trial of combined insulin-like growth factor 1 and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab. 1996; 81:2968-75. Google Scholar15. Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 1989; 321:1797-803. Google Scholar16. Vandeweghe M, Taelman P, Kaufman JM. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin Endocrinol (Oxf). 1993; 39:409-15. Google Scholar17. Schambelan M, Mulligan K, Grunfeld C, Daar ES, LaMarca A, Kotler DP, et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Ann Intern Med. 1996; 125:873-82. Google Scholar18. Roubenoff R, Kehayias JJ, Dawson-Hughes B, Heymsfield SB. Use of dual-energy x-ray absorptiometry in body-composition studies: not yet a “gold standard.” Am J Clin Nutr. 1993; 58:589-91. Google Scholar19. Steele FR. Growth hormone and AIDS-related wasting [News]. Nat Med. 1996; 2:369-70. Google Scholar20. Baum HB, Biller BM, Finkelstein JS, Cannistraro KB, Oppenheim DS, Schoenfeld DA, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med. 1996; 125:883-90. Google Scholar Author, Article, and Disclosure InformationAuthors: Christos S. Mantzoros, MD, DSc; Alan C. Moses, MDAffiliations: Beth Israel Deaconess Medical Center, Boston, MA 02215.Corresponding Author: Alan C. Moses, MD, GZ 800, General Clinical Research Center, Beth Israel Hospital, 330 Brookline Avenue, Boston, MA 02215.Current Author Addresses: Drs. Mantzoros and Moses: GZ 800, General Clinical Research Center, Beth Israel Hospital, 330 Brookline Avenue, Boston, MA 02215. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRecombinant Human Growth Hormone in Patients with HIV-Associated Wasting Morris Schambelan , Kathleen Mulligan , Carl Grunfeld , Eric S. Daar , Anthony LaMarca , Donald P. Kotler , Jack Wang , Samuel A. Bozzette , and James B. Breitmeyer Recombinant Human Growth Hormone, Insulin-like Growth Factor 1, and Combination Therapy in AIDS-Associated Wasting Debra Waters , Jeff Danska , Kevin Hardy , Frederick Koster , Clifford Qualls , Donna Nickell* , Stephen Nightingale , Neil Gesundheit , Durwood Watson , and David Schade Effects of Physiologic Growth Hormone Therapy on Bone Density and Body Composition in Patients with Adult-Onset Growth Hormone Deficiency Howard B.A. Baum , Beverly M.K. Biller , Joel S. Finkelstein , Kristin Baker Cannistraro , Daniel S. Oppenheim , David A. Schoenfeld , Theresa Hoskins Michel , Harriet Wittink , and Anne Klibanski Metrics Cited byMonitoring insulin-like growth factors in HIV infection and AIDSFrom hormones to immunity: the physiology of immunologyGrowth Hormone Therapy in AdultsSkeletal Muscle Function in COPDSpezialpräparateSkeletal Muscle Dysfunction in Chronic Obstructive Pulmonary DiseaseGrowth Hormone and Growth Hormone Secretagogues in AdultsSpezialpräparateRecombinant human growth hormone: old and novel usesInvoluntary Weight Loss in Elderly Outpatients: Recognition, Etiologies, and Treatment 1 December 1996Volume 125, Issue 11 Page: 932-934 Keywords Adipose tissue Body weight Bone density Elderly Growth factors Growth hormone Human growth hormone Insulin-like growth factors Muscles Quality of life ePublished: 15 August 2000 Issue Published: 1 December 1996 Copyright & PermissionsCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...